Listeria monocytogenes Vaccines

Creative Biolabs is a world leader in the field of bacterial vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against disease caused by Listeria monocytogenes and guarantee the finest results for our customers all over the world.

Listeria monocytogenes Vaccines - Creative Biolabs

Listeria monocytogenes (L. monocytogenes) is a gram-positive, motile, facultatively anaerobic, rod-shaped, and intracellular bacterium. As the causative organism, it is responsible for listeriosis which causes invasive diseases in humans and animals, especially central nervous system (CNS) infections. It is ubiquitous and can be isolated from wild and domestic animals, birds, insects, soil, wastewater, and vegetation. The most common clinical manifestation of listeriosis is diarrhea and the mild presentation of fever, nausea, vomiting, and may resemble a gastrointestinal illness. Bacteremia and meningitis are more serious that can affect individuals at high risk, resulting in significant morbidity and mortality. Protective immunity against L. monocytogenes strongly depends on CD8+ T lymphocytes, and both IFN-γ secretion and target cell killing are considered relevant to protection.

Adenovirus-based Vaccine

The vaccine used replication-deficient adenoviruses as vehicles for transfer of L. monocytogenes, eliciting strong cellular immune responses involving both CD8+ and CD4+ T cells. Tethering of the inserted target Ag to MHC class II-associated invariant chain (Ii) greatly enhances both the presentation of most target Ags, as well as overall protection against viral infection. Protection in C57BL/6 mice against recombinant L. monocytogenes expressing an immunodominant epitope of the lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP33) was greatly accelerated, augmented, and prolonged following vaccination with an adenoviral vaccine encoding GP linked to Ii compared with vaccination with the unlinked vaccine. Moreover, vaccination of C57BL/6 (L. monocytogenes-resistant) and BALB/c (L. monocytogenes-susceptible) mice with this vaccine revealed that tethering of these Ags to Ii markedly improved the vaccine-induced CD8+ T cell response. These data all prove that the vaccine can be an effective vaccine against listeriosis.

DNA Vaccine

It was demonstrated that CD8+ T cells are induced with specificity against two immunodominant Ags of L. monocytogenes, listeriolysin and p60. The DNA vaccine was made by plasmids encoding for listeriolysin and p60 with the CpG-ODN adjuvanted. DNA immunization of BALB/c mice with the vaccine significantly increased the frequency of specific IFN-γ-secreting T cells. Vaccination with plasmid induced protective immunity against listerial challenge. Therefore, this vaccine demonstrates the feasibility of gene gun administration of plasmid DNA for inducing immunity against an intracellular pathogen like L. monocytogenes for which protection primarily depends on type 1 CD8+ T cells.

Nanoparticle Vaccine

Multivalent glycoconjugates based on gold glyconanoparticles (GNP) were used to generate an L. monocytogenes based GNP nanovaccine by covalent linking of glucose and a peptide representing the L. monocytogenes T-cell epitope (LLO91–99) to the GNP metallic core thereby creating GNP-LLO91-99 nanoparticles. This nanovaccine was shown to be free of cytotoxicity, effectively delivered the L. monocytogenes epitope to DC in vitro and in vivo and induced effective CD8+ T-cell immunity. In addition, the nanovaccine was combined with the novel polysaccharide nanoparticle adjuvant which is derived from delta inulin microparticles and has been shown to induce robust CD4+ and CD8+ T-cell responses. This offers an opportunity to produce a cheap and reliable L. monocytogenes vaccine for use as a conventional prophylactic vaccine for all individuals at risk of listeriosis.

Creative Biolabs is a highly proactive, robust and diversified company with a strong, scientifically-proven background of bacterial vaccine development. We have experts who are able to help you with the vaccine development against diseases caused by Listeria monocytogenes. If you are interested in our services, please contact us for more details.


Our services are for research use only. We do not provide services directly to individuals.


Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

CONTACT US

USA
45-1 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-466-5530
Fax: 1-631-207-8356
Email:
Europe
UK - Germany
Email:


Follow us on

facebook   twitter   linked   blog

Shopping Basket